Keyword
in
Collection
Date
to
Houston Voice, No. 920, June 12, 1998
File 027
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 920, June 12, 1998 - File 027. 1998-06-12. University of Houston Libraries. University of Houston Digital Library. Web. August 11, 2020. https://digital.lib.uh.edu/collection/montrose/item/3055/show/3032.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1998-06-12). Houston Voice, No. 920, June 12, 1998 - File 027. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/3055/show/3032

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 920, June 12, 1998 - File 027, 1998-06-12, Montrose Voice, University of Houston Libraries, accessed August 11, 2020, https://digital.lib.uh.edu/collection/montrose/item/3055/show/3032.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 920, June 12, 1998
Contributor
  • Hennie, Matthew A.
Publisher Window Media
Date June 12, 1998
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 027
Transcript New Funds Help AIDS Patients With Treatment JACKSON. Miss. — Mississippians who were left in limbo when federal money for their AIDS treatment dried up last year are still receiving medicine with the assistance of emergency funds, health officials say. And with the addition of 5750,000 Mississippi lawmakers put aside for AIDS medicine, more patients will soon be eligible for treatment, said Dr. Bob Hotchkiss. director of the Health Department's Office of Community Health Services. The state money will be available July I. "Everybody who was eligible for the program and was not on Medicaid or on private insurance when it ended are still being treated," Hotchkiss said. "Of the people who went off. lhe mosi left because they were on Medicaid." Hotchkiss said crusades by stale and federal AIDS advocates helped the state secure an additional S860.000 from the Ryan White AIDS program when money for lhe federally funded AIDS Drug Assistance Program, commonly called ADAP. ran oul. Hotchkiss said 192 people are still receiving medicine financed with the emergency funds, which were award ed earlier this year. He said the department is trying to accept as many new applications as it can. But Debbie Konkle-Parker, chairwoman of the Mississippi HIV/AIDS Assembly, said more than 200 people are still waiting for treatment. AIDS Deaths Down By Half in Missouri JEFFERSON CITY. Mo. — Fewer Missourians are dying of AIDS, the stale Department of Health said. AIDS deaths in Missouri dropped by more lhan half in 1997 compared to 1996. and two-thirds from the peak year in 1995. said health department direcior Dr. Maureen Dempsey. Dempsey said there were 163 AIDS deaths in 1997. That compared to 339 deaths in 1996. and 502 in 1995. The decline reflects a national trend, Dempsey said. From 1995 to the first half of 1997, the national AIDS death rate dropped 59 percent. During the same period in Missouri, the death rate dropped 62 percent. Dempsey said the decreased AIDS mortality is largely the result of improvements in the treatment of HIV-infected people. Specifically, she cited the increasing use of combina tions of antiretroviral drugs thai include protease inhibitors. Study Says Outpatient Mastectomies Present No Extra Health Risk WASHINGTON — Medicare breast cancer patients wilh no other disease who undergo mastectomies as outpatients face about the same risk of complications as women who spend a nighl In the hospital after the surgery, federal researchers report. Their study, published June 3 in the Journal of the National Cancer Institute, supports lhe idea that many women will do better following mastectomy if they remain in the hospital for at least one night, but it also shows that an outpatient procedure is "a reasonable option" for elderly women who have no other type of health problem. A number of states, including Georgia have considered laws banning so-called "drive-thru mastectomies," and two bills have been proposed in Congress to require insurance companies to pay for hospitalization if that is the choice of the palient and her physician. Aboul 1 1 percent of breast cancer patients on Viramune (nevirapine)CQO Simple maintenance dose: one 200 mg tablet twice daily BRIEF SI WARNING VIRAMUNE i-Hf/lflAPINE. IS INDCA1ED FOR USt Ifl COMBINATION WITH NUCLEOSIW ANMOGylS FOfl ri-E -RWMEN' ■•■■ . ■ Nffi -fO JJ.1JLTS WHD HM E.<«SifNCE: : *.';.'. ■'•'.: OP MMUNfi! ""air: uETEPIOflATICN THIS WHXICN - BASF I 111 *.« ,-SiSOl iXAFffiEMN 51.RR0GA1E ■•:.:■ ■;:!.*;.!. ■1TU0SS OF JF TO « WEE- ;i.-;' N l-HESWl -■:>• ifiFW -'■ HIS FROM i NtfiOl EDCHN ICAL TRIALS EV*U«WG WE EFFECT OF VWWMK WIM WJCIEOSKE MWOSuES OK IRE CLINICAL PROGRESSION OF mv-t IWECTI0N. SUCH AS THE INCIDENCE OF OPPORTUNISTIC INFECTIONS OB SUA WAI THE DURATION OF BENEFIT FROM WI RETROVIRAL THERAPY MAY BE LIMITED ALTERATION OF ANTI* RETROVIRAL THERAPIES SHOULD BE CONSIDERED IF DISEASE PROGRESSION OCCURS WHIIE PATENTS ARE RECEMHG VIRAMUNE RESISTANT VIRUS EMERGES RAPIDLY AND UNIFORMLY WHEN VIRAMUNE IS ADMINISTERED AS MONOTHERAP' THEREFORE ;IF>AMUNE SHOULD ALWAYS t! M'MiNIS- ERFC IN OMBINATION WUH AT LEAST ONE AOOITONAL ANTIRE TR0V1RAL AGENT VIRAMUNE HAS BEEN ASSOCIAIED WITH SEVERE RASH WHICH IN SOME CASES HAVE BEEN LIFE* THREATENING WHEN SEVERE RASH OCCURS VIRAMUNE MUST BE DISCONTINUED Mrnuif Molhts. Preliminary results Iram an ongoing pharmacokinetic study (ACTG 2M| ol 10 HIV-1* mfected piegnanl women who were administered a single oral dose ol 100 or 200 m_ VIRAMUNE * at a median ol 5fi hours before delivery, indicate lhal nevirapine readily crosses lite placefila and is found m breasl nulk Consistent with the iKommemlalion By lhe U S Public Health Service Cenleis lor Disease Control and Prevention thai HIV-inlected mothers nol breast leed their infants Id jvu-'J iM ng postnatal transmission ol HIV. mothers should discontinue nursing il they are receiving VIRAMUNE rritiitrtc 0a: Safety and effectiveness of VIRAMUNE" m pediatric patients have nol been established VIRAMUNE has Deen studied in two open-label uncontraHed trials {Bl 887. Bl B92) in 37 HIV-1 infected pediatric paMnts with a median age ol 09 years (range o 1 to IS years) who were treated lor a median iluralion ill ?■', ' nonius W [.-.n -^ '■*■ de-/eioped iasn« nhr* 'ecening VIRAMUNE u in ongoing controled inal ol VIRAMUNE combination therapy in HIV 1 mlecled pediatric (Blunts (ACTG 245). one ol apptoumatety !88 patents treated wilh VIRAMUNE eiperienced Sievens-Johnson syndrome Because there are no data on mum-dose phaimacoluneiics in children no tecommendalwxi on dosing can be made Based on smgle-dose pharmacokinetics m 9 HIV-1 mleciefl pediatric patients |age 9 mos ■to weie adminlsleied nevmpma m a suspension formulation, it appears that oial clearance is appionmalely 2 low greaKr in children when compared lo adults ADVERSE REACTIONS: Tne rnosi frequently leporled adverse evenls related to VIRAMUNE' iherapy were The in. with VIRAMUNE eiperienced rash compared wilh 20% ol pabents trealed m control groups ot eilher ZDV.ddt or ZDV alone (Table 1) Severe or We-lhrratehing rash occurred in 76% 01 VIRAMUNE -Irealed patients compared with i 2% ol palienls irealed m lhe control groups Rashes are ustia«y imld to moderale. maciiopacuUr erythemafous cutaneous eruptions, wilh or without pruritus located on lhe Irunk. face and ettreimties The maiorily ol severe rashes occurred within the fust 28 days ol Ireatmenl. 25% ol the patients with severe rashes reauired hosgrtaluatlon. and one panen! required surgical infeivention All palienls recoveied Overall. 7% ol patients discontinued VIRAMUNE due to rash Tablet Percentage of pahents with rashes m conlralled trials*1 CONTRAINDICATIONS VIRAMUNE ■ ■ ■ : WARNINGS Senere and life-threatening rtm reactm* have Murrtd Patienh ADVERSE REACTIONSl VIRAMUNE therapy rm to reduce the frequency ot rash Dose escalation should not occur H rash a observed dumg Bus lead-m period until me lash has resolved (see DOSAGE AND ADMINISTRATION) PRECAUTIONS: Gmmttl When administering VIRAMUNE as pari ol an anliietroviral treatment regimen fhe complete producl mformation tor each Iheiapeutic component should be consulted belore mrtaiion WIS HI1 Bl1037 Bl 1011 COMBINED DMA NVF..'[.». ZDV-Otti N'.Ct', ZDV v, ■■■..■:-■. zm* Ml ;dniroi n 197 Ki 30 30 a H Z52 255 Rash events ol ail Grades aid.»rji.satty »6: 22?, 6 7'. £ V. ■ U 37 M MOS events, an causality 81", Ii', 3 3-. Oh 8 [fa D% in, 12% id dose ot one 200 mg tablef daHy !■» the lusi 14 days KMmmS by one 200 mg tablel While nevuapine ver and nevirapine melabofiles are e.tensively ■ "non Therelore VIRAMUNE should Oe used with caution in Ihese patient on ol CVP3A by ne ed Otuas that are eriensiufy td bv CYP3A (see CLINICAL PHARMACOLOGY) This if a patient has been stabilized on a dosage regimen for a diug metabolized by CYP3A. and begins treatment with VIRAMUNE* dose ad|ust ments may be necessary RitanymyHilatMin There are insufficient data lo assess whether dose ad-ustments are necessary when nevmacme and ntamom a ntaouirn aie coadnwustered Therelore these drugs should only Be used in >l clearly unhealed and wilh careful monitoring Mxtort: Nevirapine may decrease plasma concenliations ol protease mhtbitois Therefore. -s. these drugs Would not be a the nodence or Irequency ol ild Be advised to remain under lhe care ol a [fcysoan when using VIRAMUNE X informed that the long-term effects of VIRAMUNE are unknown at ttto Wnt They Table 2 lists Ireatmenl-related cluneal adverse evenls lhat occur re ACTG 241 and ii Trials Bl 1037 and 611011 Table! Comparative Incidence ol Selected Drug-Related Evenls m in patients receiving VIRAMUNE m Controlled Trials ACTG 241 Inal 811037 and Bi 1011 ;■.::■ Mm ■ •J MMM ■l.-O'. ■ :-.: ZDVtidl MVP .ZDV ZDV a.one NURaaMI V pflMMi 197 201 55 30 OflH-ncdeneol 31% ZK ■;■■ m Rash i 2 20 3 Fever 3 3 11 3 Nausea 5 4 9 3 HwMM 3 3 11 D Duimea 2 2 0 0 UgnMlW t 2 7 0 Ulcerative stomatitis 0 0 4 0 Peripheral Neuropathy 0 2 3 0 Paraesthesia 1 0 2 0 1 0 2 7 1 0 * 0 msN***- Table 3 summarizes marked laOoutny abnormalities occurring in three controlled id other hormonal methods ot birth control a method ol contraception in women taking VIRAMUNE in ol ftrlillty .ong le'm carcinogenicity studies ol nevirapine Table 3 Percentage ol palienls with ma kedlabdraloryabno Oata combined 'or controlled trials ACTG 341 BMO371BH0tt VIRAMUNE Control Decreased Hg (<B 0 g-dLi Oecnaud platelets i<S0 Offi-nm i Decieased nculropMs (<750Mm:) ________ _<-t___l____, .ncreaseoALTi-.2SOU.li increaseOAST|>250U.H Increased GGT MM U-l. increased lolaiCilirutrei 1*2 5 mj'OLi 12% OB 111 34 u 24 M 20% 08 102 35 12 12 OVFRD0SAGE Tnere.snonnownant.dotelO'ViRAt/^NE overdosaoe Noac .gested S0C mg ot VIRAMUNE' loi one CAUTION FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION ts providing systemic e.posuieapb' „™iel, SC i.gnei m-,.,: m AUC than lhal seen at Ihe rec nenoed human clmicai dose 'he matemji ond developmental ncohservaWeelfect level sosages m md ntatnts moduom tvstenuc e/nosures aptHonmaleiy eauvalent to ot apprommalet' 50% tugher -J>d duy human dose Based onAUC There ve no adequate n VIRAMUNE should Be used during gregnancy only if I Roxane Latxira tones. Inc d tvatm mi Medicare who undergo masterlomies do so as outpatients. Hepatitis C Cocktail Combination Therapy Wins FDA Approval MADISON, N.J. — Sparked by the apparent effectiveness of combination therapy in the treatment of HIV/AIDS, the FDA has now approved a new combination therapy for chronic Hepatitis C patients with liver disease. Schering- Plough Corporation announced June 3 that the U.S. Food and Drug Administration has approved the combination use of Rebetol capsules and Intron A Injection, to be marketed as rebetron combination Iherapy, for the treatment of chronic hepatitis C in patients with liver disease who have relapsed following alpha interferon therapy. Prior to the combination therapy, the only drugs approved in the United States for treating hepatitis C had been alpha interferons. "Rebetron combination therapy is an exciting treatment breakthrough," said Willis C. Maddrey, M.D.. professor of medicine at the University of Texas Southwestern Medical Center in Dallas and a world-renowned hepatologfst Viagra Maker Joins others in Hunt for Female Orgasm Pill' LONDON — The drug company that produced thc male sex pill Viagra is now hoping to repeal its success with a simitar one for women, the London Sunday Times reported June 7. It said multinational Pfizer is one of three big drug companies racing to market tlie first "orgasm pill" for women. The paper reported thai initial results from secret clinical trials nmnnissioiu'd by Pfizer in Britain suggest the treatment is effective. Pfizer is said to be Inveati gating three diflerenl formulations of sildenafil, the active Ingredient in Viagra, In trials among more Lhan 500 women across Europe. Those laking the drug, compared with those taking .i placebo, reported an increase In the number ol times they had sex wilh their husbands. The paper said US manufacturer Zonagen has begun hi als wilh anolher drug known as Vasomax which dilates blood vessels. Abbott Laboratories In Chicago are testing another compound called apo- morphine which stimulates receptors in the brain, it added. Viagra is already the subject of 100.000 prescriptions a week in the U.S. Doctors Wary Over Heart Disease in AIDS Patients Using Protease WASHINGTON — At least two researchers have indicated they have seen patients on protease inhibitors who are experiencing heart-related problems on the drugs, according to a report in The Washington Blade. Dr. Donald Abrams. an AIDS clinician at the University of California-San Francisco, said that he has seen a few patients on protease inhibitor combinations for two years who have begun to develop coronary heart disease, the gay newspaper reported. Dr. Keith Henry and a Minnesota-based team of researchers reported in the May 2 issue of the British medical journal The Lancet that about one-third of 124 patients they have been following on protease inhibitors have developed some heart disease. The researchers suggested thai patients initialing pro lease therapies be tested for suscepti bilily to such hear) disease. —From staff and \rin- reports
File Name uhlib_31485329_n920_026.jpg